COCRYSTAL PHARMA NEW O.N. (8CC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COCRYSTAL PHARMA NEW O.N. (8CC) has a cash flow conversion efficiency ratio of -0.274x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.74 Million ≈ $-2.03 Million USD) by net assets (€6.33 Million ≈ $7.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
COCRYSTAL PHARMA NEW O.N. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how COCRYSTAL PHARMA NEW O.N.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of COCRYSTAL PHARMA NEW O.N. for a breakdown of total debt and financial obligations.
COCRYSTAL PHARMA NEW O.N. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COCRYSTAL PHARMA NEW O.N. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Powerhouse Ventures Ltd
AU:PVL
|
-0.030x |
|
Loyal Lithium Ltd.
AU:LLI
|
0.010x |
|
Earlyworks Co., Ltd. American Depositary Shares
NASDAQ:ELWS
|
-1.245x |
|
Huddlestock Fintech As
OL:HUDL
|
-0.127x |
|
Honkarakenne Oyj B
HE:HONBS
|
-0.200x |
|
SSR Inc
KQ:275630
|
0.043x |
|
Shenzhen Wongtee International Enterprise Co Ltd
SHE:200056
|
1.041x |
|
Mega Polietilen Kopuk Sanayi ve Ticaret AS
IS:MEGAP
|
-0.371x |
Annual Cash Flow Conversion Efficiency for COCRYSTAL PHARMA NEW O.N. (2021–2025)
The table below shows the annual cash flow conversion efficiency of COCRYSTAL PHARMA NEW O.N. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see 8CC company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €6.33 Million ≈ $7.40 Million |
€-8.19 Million ≈ $-9.58 Million |
-1.294x | +25.25% |
| 2024-12-31 | €9.52 Million ≈ $11.13 Million |
€-16.48 Million ≈ $-19.27 Million |
-1.731x | -211.42% |
| 2023-12-31 | €26.38 Million ≈ $30.85 Million |
€-14.67 Million ≈ $-17.15 Million |
-0.556x | -2.61% |
| 2022-12-31 | €39.57 Million ≈ $46.26 Million |
€-21.43 Million ≈ $-25.06 Million |
-0.542x | -230.30% |
| 2021-12-31 | €77.55 Million ≈ $90.66 Million |
€-12.72 Million ≈ $-14.87 Million |
-0.164x | -- |
About COCRYSTAL PHARMA NEW O.N.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hep… Read more